Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients.

Telephone: +44 (0)1223 891 854
Address: Suit 2, Riverside 3, Granta Park, Great Abington
Postcode: CB21 6AD
Country: United Kingdom
Membership type:Corporate 21-50 (£500+VAT pa)

Sobi in short 

Sobi is an international specialty healthcare company dedicated to rare diseases. Our  mission is to develop and deliver innovative therapies and services to improve  the lives of patients. The product portfolio is primarily focused on  Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of  specialty and rare disease products for partner companies across Europe, the  Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with  world-class capabilities in protein biochemistry and biologics manufacturing. In  2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600  employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More  information is available at

Sobi puts on purple-themed funfair

Sobi puts on purple-themed funfair to raise funds for juvenile idiopathic arthritis (JIA)

Today, as part of its commitment to supporting people with rare diseases, Cambridgeshire-based speciality healthcare company Sobi UK and Republic of Ireland (RoI) held a purple-themed fundraising funfair event in support of the juvenile idiopathic arthirits (JIA) awareness day ‘Wear Purple for JIA.

8 June 2018Read in full

Sobi™ rated as the UK’s top haemophilia company for 2016

Swedish Orphan Biovitrum Ltd (Sobi™), the Cambridge-based UK affiliate of the international specialty healthcare company Sobi AB, today announces that it has been rated in first place among companies supplying haemophilia treatments as judged by the IPC Associates’ annual survey 2016 of this market.

9 May 2017Read in full

Sobi recognised as one of the UK’s best places to work

Cambridge-based healthcare company Sobi has been publicly recognised by Great Place to Work® as one of the UK’s Best Workplaces™ in the Small (20-49 employees) category in their annual ranking. The Best Workplace™ awards, announced this week, are considered the 'gold standard' of employer awards and publicly recognise Sobi as a great employer, brand and business.

5 May 2017Read in full

Sobi plans its first Cambridge Charity Ball

Sobi is delighted to announce its first charity ball, being held to raise money for three important charities. The ball will be held on Friday 8th April 2016 in The Great Hall at Homerton College, Cambridge, with arrival drinks from 6:30pm. Tickets are nearly gone so please get in touch if you wish to come along.

2 March 2016Read in full

Sobi initiates clinical development programmes in acute gout and Still's disease

Swedish Orphan Biovitrum AB (publ) (Sobi(TM)), today announced that it has decided to initiate two clinical programmes with Kineret® (anakinra) in North America, with the aim of evaluating two new potential indications for Kineret where a significant need for alternative treatment options exists: acute gout and Still's disease.

23 February 2016Read in full

Chief Medical Officer Birgitte Volck to leave Sobi

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that Birgitte Volck, MD, PhD, Senior Vice President of Development and Chief Medical Officer (CMO) of Sobi, will leave the company to join the rare disease research group at GlaxoSmithKline as Head of R&D Rare Diseases. Birgitte will work through a six month notice period before leaving Sobi.

15 January 2016Read in full

Lars Dreiøe joins Sobi as Senior Vice President, Chief Quality & Compliance Officer

Swedish Orphan Biovitrum AB (publ)(Sobi) has announced that Lars Dreiøe has been appointed Senior Vice President Chief Quality & Compliance Officer (CQCO). Lars Dreiøe joins Sobi from global pharmaceutical company ALK in Denmark where he has been International Head of Quality.

22 December 2015Read in full

European Medicines Agency approves Xiapex® for concurrent treatment of palpable cords

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the European Medicines Agency has approved Xiapex® (collagenase clostridium histolyticum, or CCH) for the treatment of two Dupuytren's contracture (DC) cords concurrently.

18 November 2015Read in full